Loading clinical trials...

TERMINATED

Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study

NCT01336231•Centre Francois Baclesse

View on ClinicalTrials.gov

Summary

Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient (e) Age (e) over 18 years
•Kidney cancer metastatic or locally advanced
•Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together
•Proposed treatment in first line or second line
•Brain imaging not finding brain metastases
•Having signed the informed consent of study participation
•The patient may have received prior anti-angiogenic

Exclusion Criteria

•Cancer of the kidney other than primitive
•Previous history of cancer other than kidney cancer in complete remission for less than 5 years
•Patients under 18 years
•Patients whose treatment is associated with chemotherapy
•disorders of cognitive functions to existing treatment delivery
•Pathology psychiatric evolutionary
•Refusal of participation
•Patient unable to respond to cognitive tests
•Drug use
•Heavy drinking (WHO criteria)
+4 more criteria

Locations (6)

Centre François BACLESSE

Caen, Calvados, France

Centre Henri Becquerel

Rouen, Seine Maritime, France

CHU

Rouen, Seine Maritime, France

CHU

Strasbourg, France

Institut Gustave Roussy

Villejuif, France

Hôpital Georges Pompidou

Paris, Île-de-France Region, France

Key Dates

Start Date

October 1, 2008

Primary Completion Date

June 1, 2013

Completion Date

June 1, 2013

Last Updated

July 21, 2016

Enrollment

ACTUAL participants

Conditions

Metastatic Kidney Cancer

CARE1 Pragmatic Clinical Trial

NCT06364631

Metastatic Kidney CancerMetastatic Kidney Carcinoma

View study

COMPLETEDPHASE1

Immunotherapy Study for Metastatic Renal Cell Cancer

NCT02035358

Metastatic Renal Cell CarcinomaMetastatic Clear-cell Renal Cancer+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Inclusion Criteria

Exclusion Criteria

CARE1 Pragmatic Clinical Trial

Immunotherapy Study for Metastatic Renal Cell Cancer

ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib

Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer